Prior Aerosol Infection with Lineage A SARS-CoV-2 Variant Protects Hamsters from Disease, but Not Reinfection with B.1.351 SARS-CoV-2 Variant
Overview
Authors
Affiliations
The circulation of SARS-CoV-2 has resulted in the emergence of variants of concern (VOCs). It is currently unclear whether the previous infection with SARS-CoV-2 provides protection against reinfection with VOCs. Here, we show that low dose aerosol exposure to hCoV-19/human/USA/WA-CDC-WA1/2020 (WA1, lineage A), resulted in a productive mild infection. In contrast, a low dose of SARS-CoV-2 via fomites did not result in productive infection in the majority of exposed hamsters and these animals remained non-seroconverted. After recovery, hamsters were re-exposed to hCoV-19/South African/KRISP-K005325/2020 (VOC B.1.351) via an intranasal challenge. Seroconverted rechallenged animals did not lose weight and shed virus for three days. They had a little infectious virus and no pathology in the lungs. In contrast, shedding, weight loss and extensive pulmonary pathology caused by B.1.351 replication were observed in the non-seroconverted animals. The rechallenged seroconverted animals did not transmit the virus to naïve sentinels via direct contact transmission, in contrast to the non-seroconverted animals. Reinfection with B.1.351 triggered an anamnestic response that boosted not only neutralizing titres against lineage A, but also titres against B.1.351. Our results confirm that aerosol exposure is a more efficient infection route than fomite exposure. Furthermore, initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351 but prevents disease and onward transmission. These data suggest that previous SARS-CoV-2 exposure induces partial protective immunity. The reinfection generated a broadly neutralizing humoral response capable of effectively neutralizing B.1.351 while maintaining its ability to neutralize the virus to which the initial response was directed against.
Wang S, Li W, Wang Z, Yang W, Li E, Xia X Signal Transduct Target Ther. 2024; 9(1):223.
PMID: 39256346 PMC: 11412324. DOI: 10.1038/s41392-024-01917-x.
Darling T, Harastani H, Joshi A, Bricker T, Soudani N, Seehra K Sci Adv. 2024; 10(31):eadp1290.
PMID: 39083604 PMC: 11290484. DOI: 10.1126/sciadv.adp1290.
Port J, Yinda C, Riopelle J, Weishampel Z, Saturday T, Avanzato V Nat Commun. 2023; 14(1):6592.
PMID: 37852960 PMC: 10584863. DOI: 10.1038/s41467-023-42346-8.
Francis M, Jansen E, Yourkowski A, Selim A, Swan C, MacPhee B Nat Commun. 2023; 14(1):5990.
PMID: 37752151 PMC: 10522707. DOI: 10.1038/s41467-023-41761-1.
Barrett E, Revelli D, Bakshi C, Kadish A, Amar S Front Microbiol. 2023; 14:1212179.
PMID: 37293233 PMC: 10244709. DOI: 10.3389/fmicb.2023.1212179.